Valbiotis: Rises as cholesterol drug phase II study green-lighted

Valbiotis SA

16/02/2021 09:09

** Shares in Valbiotis rise 3.5% after the French biotech
company received authorisation from the French medicine safety
agency (ANSM) for phase II of its HEART clinical study for the
reduction of cholesterol levels in blood
    ** The main objective of the clinical study is to evaluate
the efficacy of a 5g daily dose of TOTUM-070 and to confirm its
safety
    ** Results are expected at the beginning of 2022
    ** Valbiotis shares currently trade at 8.1 euros, their
highest price since May 2018

 ((federica.mileo@thomsonreuters.com))